Development and investigation of a novel device with gemcitabine for hyperthermic intravesical chemotherapy

References

• Ferlay J, Soerjomataram I, Globocan EM. Estimated cancer incidence, mortality and prevalence worldwide in 2012, 2013, 2015. 2012. http://globocaniarcfr/Defaultaspx
   Google Scholar
• Sylvester RJ, Van Der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):465–466.
   PubMed Web of Science ®Google Scholar
• Babjuk M, Burger M, Compérat E, et al. [EAU guidelines] Non-muscle invasive Bladder Cancer. 2019. Available from: https://uroweborg/guideline/non-muscle-invasive-bladder-cancer/
   Google Scholar
• Tan WS, Panchal A, Buckley L, et al. Radiofrequency-induced thermo-chemotherapy effect versus a second course of bacillus Calmette-Guérin or institutional standard in patients with recurrence of non-muscle-invasive bladder cancer following induction or maintenance bacillus Calmette-Guérin therapy (HYMN): a phase III, open-label, randomised controlled trial. Eur Urol. 2019;75(1):63–71.
   PubMed Web of Science ®Google Scholar
• Tan WS, Kelly JD. Intravesical device-assisted therapies for non-muscle-invasive bladder cancer. Nat Rev Urol. 2018;15(11):667–685.
   PubMed Web of Science ®Google Scholar
• Zhou J, Li L, Li X, et al. Efficacy analysis of a novel thermochemotherapy scheme with pirarubicin for intermediate- and high-risk nonmuscle-invasive bladder cancer: a single-institution nonrandomized concurrent controlled trial. Int J Hyperthermia. 2019;36(1):868–875.
   PubMed Web of Science ®Google Scholar
• Ruan Q, Ding D, Wang B, et al. A multi-institutional retrospective study of hyperthermic plus intravesical chemotherapy versus intravesical chemotherapy treatment alone in intermediate and high risk nonmuscle-invasive bladder cancer. Cancer Biol Med. 2021;18(1):308–317.
   PubMed Web of Science ®Google Scholar
• Ba M, Cui S, Long H, et al. Development of a high-precision bladder hyperthermic intracavitary chemotherapy device for bladder cancer and pharmacokinetic study. BMC Urol. 2019;19(1):126.
   PubMed Web of Science ®Google Scholar
• Van Der Heijden AG, Dewhirst MW. Effects of hyperthermia in neutralising mechanisms of drug resistance in non-muscle-invasive bladder cancer. Int J Hyperthermia. 2016;32(4):434–445.
   PubMed Web of Science ®Google Scholar
• Raoof M, Zhu C, Cisneros BT, et al. Hyperthermia inhibits recombination repair of gemcitabine-stalled replication forks. J. Natl Cancer Inst. 2014;106(8):183.
   Google Scholar
• Akaza H, Umbas R, Cheng JC-H, et al. NCCN clinical practice guidelines in oncology [NCCN guidelines]. Asia consensus statements Bladder Cancer. Version 1; 2016. https://www.nccn.org/professionals/physician_gls/pdf/bladder-asia.pdf
   Google Scholar
• Ba MC, Cui SZ, Lin SQ, et al. Chemotherapy with laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion for malignant ascites. WJG. 2010;16(15):1901–1907.
   PubMed Web of Science ®Google Scholar
• Zhang MM, Li J, Pang TY, et al. Thermal stability study of gemcitabine hydrochloride used in hyperthermic intravesical chemotherapy. Chin. J. Hosp. Pharm. 2022;42(16):50–56.
   Google Scholar
• Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why and how. BMC Med Res Methodol. 2010;10:1.
   PubMed Web of Science ®Google Scholar
• Cocks K, Torgerson DJ. Sample size calculations for pilot randomized trials: a confidence interval approach. J Clin Epidemiol. 2013;66(2):197–201.
   PubMed Web of Science ®Google Scholar
• Brausi M, Collette L, Kurth K, EORTC Genito-Urinary Tract Cancer Collaborative Group, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol. 2002;41(5):523–531.
   PubMed Web of Science ®Google Scholar
• Arends TJ, Nativ O, Maffezzini M, et al. Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus Calmette-Guérin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer. Eur. Urol. 2016;69(6):1046–1052.
   PubMed Web of Science ®Google Scholar
• Colombo R. Combined treatment with local thermo-chemotherapy for non muscle invasive bladder cancer. The present role in the light of acquired data and preliminary cumulative clinical experiences. Arch Ital Urol Androl. 2008;80(4):149–156.
   PubMedGoogle Scholar
• Sousa A, Inman BA, Piñeiro I, et al. A clinical trial of neoadjuvant hyperthermic intravesical chemotherapy (HIVEC) for treating intermediate and high-risk non-muscle invasive bladder cancer. Int J Hyperthermia. 2014;30(3):166–170.
   PubMed Web of Science ®Google Scholar
• Apodaca G. The uroepithelium: not just a passive barrier. Traffic. 2004;5(3):117–128.
   PubMed Web of Science ®Google Scholar
• Kuroda M, Niijima T, Kotake T, et al. Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer–the 6th trial of the japanese urological cancer research group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20mg/40ml, 30mg/40ml, 40mg/40ml. Eur. Urol. 2004;45(5):600–605.
   PubMed Web of Science ®Google Scholar
• Paroni R, Salonia A, Lev A, et al. Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma. Br J Clin Pharmacol. 2001;52(3):273–278.
   PubMed Web of Science ®Google Scholar
• Myers AL, Zhang YP, Kawedia JD, et al. Solubilization and stability of mitomycin C solutions prepared for intravesical administration. Drugs R D. 2017;17(2):297–304.
   PubMed Web of Science ®Google Scholar
• Beijnen JH, Den Hartigh J, Underberg WJ. Quantitative aspects of the degradation of mitomycin C in alkaline solution. J Pharm Biomed Anal. 1985;3(1):59–69.
   PubMed Web of Science ®Google Scholar
• Grimberg DC, Shah A, Tan WP, et al. Hyperthermia improves solubility of intravesical chemotherapeutic agents. Bladder Cancer. 2020;6(4):461–470. Preprint
   PubMed Web of Science ®Google Scholar
• De Berardinis E, Antonini G, Peters GJ, et al. Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation. BJU Int. 2004;93(4):491–494.
   PubMed Web of Science ®Google Scholar
• Dalbagni G, Russo P, Bochner B, et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder. J Clin Oncol. 2006;24(18):2729–2734.
   PubMed Web of Science ®Google Scholar
• Tan WP, Longo TA, Inman BA. Heated intravesical chemotherapy: biology and clinical utility. Urol Clin North Am. 2020;47(1):55–72.
   PubMed Web of Science ®Google Scholar